SEVEN DAYS

摘要

Drug giant GlaxoSmithKline will pay US$3 billion in fines for enormous health-care fraud. The firm, headquartered in London, is pleading guilty to promoting antidepressants for unapproved use, and to holding back data and making unsupported safety claims about its diabetes drug Avandia (rosiglitazone). The settlement was announced last November, but legal documents detailing the guilty pleas were unsealed on 2 July.